Compare SoFi Technologies Inc (SOFI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

SoFi Technologies stock trades at $14.22, down 6.63% with bearish technical signals. The company shows strong revenue growth from $2.6B in 2024 to $3.6B in 2025, with consistent earnings beats. However, negative operating cash flow and high P/E ratio of 31.1 present valuation concerns. Recent news highlights SoFi's stablecoin initiatives and record loan originations while the stock faces pressure from rising yields.

SoFi offers growth potential with expanding financial services but faces execution risks in a competitive fintech landscape. The stock trades at a discount to analyst consensus target of $21.08, though negative cash flow trends and market sensitivity to interest rates warrant caution. Investors should weigh strong fundamentals against technical weakness and macroeconomic headwinds.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.